Rolling Out a Global Business Strategy
First written in FY2016. 21 of 41 entries say "Worsened", first in FY2018-Q1. Latest entry: 2026-08-05.
Techno Medica moved to the "Worse" side of this theme in 2026, 5 years after the typical company in this theme (2021).
The whole theme swung hardest in 2020: 13 of 73 companies on the "Worse" side.
5 other companies' latest entry also says "Worsened".
- 2026-08-05WorsenedEarnings
「The ratio of overseas sales to total net sales declined by 2.6 percentage points year on year to 14.6%.」
The overseas sales ratio declined year on year, reducing the share of overseas operations in total company sales. - FY2026WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 1 percentage point from the previous fiscal year to 12.8%.」
The overseas sales ratio fell from 13.8% in the previous fiscal year to 12.8%. Although overseas sales themselves increased for blood collection tube preparation systems and systems and for specimen testing systems, their contribution to company-wide sales contracted. - FY2026-H1WorsenedAnnual report
「In overseas markets, sales, mainly in Southeast Asia, exceeded the level in the same period of the previous year, and sales amounted to ¥203.674 million, up 16.0% year on year. The ratio of overseas sales to total sales decreased by 0.1 percentage points year on year to 17.0%.」
Sales of blood collection tube preparation systems and systems to Southeast Asia increased by 16.0%, while the overseas sales ratio fell by 0.1 percentage points year on year to 17.0%. The overseas business's contribution to sales contracted slightly. - FY2025AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 4.5 percentage points from the previous fiscal year to 13.8%.」
The overseas sales ratio rose from 9.3% in the previous fiscal year to 13.8%, increasing the overseas business's contribution to sales. - FY2025-H1AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 3.9 percentage points year on year to 17.1%.」
The overseas sales ratio rose by 3.9 percentage points year on year to 17.1%. This demonstrates measurable progress in increasing the overseas business's contribution to sales. - FY2024WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 2.4 percentage points from the previous fiscal year to 9.3%.」
The overseas sales ratio fell from 11.7% in the previous fiscal year to 9.3%. In overseas markets, delays in projects for China and South Korea and intensifying competition with rivals have caused the global business's contribution to sales to contract. - FY2024-Q3WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 1.1 percentage points year on year to 11.5%.」
The overseas sales ratio fell by 1.1 percentage points year on year to 11.5%, and the overseas business's contribution to sales contracted from the level through the previous quarter. - FY2024-Q2AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 0.6 percentage points year on year to 13.2%.」
The overseas sales ratio rose by 0.6 percentage points year on year to 13.2%. The increase in the overseas business's contribution to sales from the same period of the previous year represents measurable progress. - FY2024-Q1WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 0.5 percentage points year on year to 13.2%.」
The overseas sales ratio fell by 0.5 percentage points year on year to 13.2%, and the global business's contribution to sales contracted. - FY2023AdvancedAnnual report
「In the fiscal year ended March 2023, overseas sales amounted to ¥1,099.196 million, up 6.1% from the previous fiscal year, and overseas sales accounted for approximately 11.7% of total sales.」
Overseas sales increased by 6.1% from the previous fiscal year, while the overseas sales ratio rose from approximately 10.7% to approximately 11.7%. This represents tangible full-year progress in expanding sales in overseas markets. - FY2023-Q3WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 0.3 percentage points year on year to 12.6%.」
The overseas sales ratio fell by 0.3 percentage points year on year to 12.6%, and the overseas business's contribution to sales contracted. - FY2023-Q2WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 0.7 percentage points year on year to 12.6%.」
The overseas sales ratio fell from 13.3% in the same period of the previous year to 12.6%, and the global business's contribution to sales contracted. - FY2023-Q1WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 0.2 percentage points year on year to 13.7%.」
The overseas sales ratio fell from 13.9% in the same period of the previous year to 13.7%. Although the policy of expanding overseas sales continues, progress in the global business has deteriorated on a sales-contribution basis. - FY2022Higher overseas sales and a lower sales mixAnnual report
「In overseas markets, we will also seek to expand sales of products that capitalize on our technological capabilities. In the fiscal year ended March 2022, overseas sales amounted to ¥1,035.514 million, up 3.9% from the previous fiscal year, and overseas sales accounted for approximately 10.7% of total sales.」
While overseas sales increased by 3.9% from the previous fiscal year, their contribution to sales fell from approximately 11.0% to approximately 10.7%. The increase in overseas sales and the decline in their contribution are both noted in connection with overseas expansion. - FY2022-Q3WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 0.7 percentage points year on year to 12.9%.」
The overseas sales ratio fell by 0.7 percentage points year on year to 12.9%, and the global business's contribution to sales contracted from the same period of the previous year. - FY2022-Q2WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 1.6 percentage points year on year to 13.3%.」
The overseas sales ratio fell by 1.6 percentage points year on year to 13.3%, and the overseas business's contribution to sales contracted from the same period of the previous year. - FY2022-Q1AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 0.4 percentage points year on year to 13.9%.」
The overseas sales ratio rose from 13.5% in the same period of the previous year to 13.9%. This demonstrates measurable progress in increasing the global business's contribution to sales. - FY2021AdvancedAnnual report
「In the fiscal year ended March 2021, overseas sales amounted to ¥996.398 million, up 17.0% from the previous fiscal year, and overseas sales accounted for approximately 11.0% of total sales.」
Overseas sales increased by 17.0% from the previous fiscal year, while the overseas sales ratio rose from approximately 8.7% to 11.0%. This indicates progress in expanding overseas sales channels. - FY2021-Q3AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 4.9 percentage points year on year to 13.6%.」
The overseas sales ratio rose by 4.9 percentage points year on year to 13.6%, increasing the global business's contribution to sales from the same period of the previous year. - FY2021-Q2AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 7 percentage points year on year to 14.9%.」
The overseas sales ratio rose by 7 percentage points year on year to 14.9%, indicating continued expansion in the global business's contribution to sales. - FY2021-Q1AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 6.1 percentage points year on year to 13.5%.」
The overseas sales ratio rose by 6.1 percentage points year on year to 13.5%. Even as total sales declined, measurable progress was demonstrated through the increase in the overseas business's contribution to sales. - FY2020WorsenedAnnual report
「In the fiscal year ended March 2020, overseas sales amounted to ¥851.783 million, down 20.3% from the previous fiscal year, and overseas sales accounted for approximately 8.7% of total sales. Depending on future overseas expansion, we may face foreign exchange risk, risks related to contracts with overseas distributors, and risks related to maintenance and management.」
Overseas sales decreased by 20.3% from the previous fiscal year, and the overseas sales ratio fell from 11.4% to 8.7%. While the company is targeting expanded sales in overseas markets, its full-year global expansion performance has deteriorated. - FY2020-Q3WorsenedAnnual report
「As a result, sales for the cumulative third quarter amounted to ¥6,915.845 million, up 12.3% year on year. The ratio of overseas sales to total sales decreased by 5.3 percentage points year on year to 8.7%.」
The overseas sales ratio fell by 5.3 percentage points year on year to 8.7%. The global business has deteriorated year on year as the overseas market's contribution to sales contracted. - FY2020-Q2WorsenedAnnual report
「As a result, sales for the cumulative second quarter amounted to ¥4,704.692 million, up 12.9% year on year. The ratio of overseas sales to total sales decreased by 6.8 percentage points year on year to 7.9%.」
The overseas sales ratio fell by 6.8 percentage points year on year to 7.9%, and the global business's contribution to sales contracted. - FY2020-Q1WorsenedAnnual report
「As a result, sales for the cumulative first quarter amounted to ¥2,197.701 million, up 21.1% year on year. The ratio of overseas sales to total sales decreased by 4.9 percentage points year on year to 7.4%.」
The overseas sales ratio fell by 4.9 percentage points year on year to 7.4%, and the global business's contribution to sales, which had recovered from the previous fiscal year, contracted again. - FY2019AdvancedAnnual report
「As orders for blood collection tube preparation systems increased in the Asian market, we actively pursued sales in overseas markets to further expand the market. As a result, sales for the fiscal year amounted to ¥9,332.420 million, up 7.8% from the previous fiscal year. The ratio of overseas sales to total sales increased by 1.6 percentage points from the previous fiscal year to 11.4%.」
The overseas sales ratio rose from 9.8% in the previous fiscal year to 11.4%, driven by increased orders for blood collection tube preparation systems in the Asian market and overseas sales activities. - FY2019-Q3AdvancedAnnual report
「In the specimen testing systems business, we continued active sales efforts centered on our core blood gas analyzers. As a result, sales for the cumulative third quarter amounted to ¥6,158.477 million, up 8.0% year on year. The ratio of overseas sales to total sales increased by 3.9 percentage points year on year to 14.0%.」
We continued sales activities centered on our core blood gas analyzers, and the overseas sales ratio rose by 3.9 percentage points year on year to 14.0%. The increase in the overseas business's contribution to sales is confirmed. - FY2019-Q2AdvancedAnnual report
「In overseas markets, sales to Asia, mainly China, remained strong, and sales amounted to ¥364.436 million, up 184.3% year on year. The ratio of overseas sales to total sales increased by 5.3 percentage points year on year to 14.7%.」
Sales to Asia, mainly China, increased by 184.3% year on year, while the overseas sales ratio rose to 14.7%. It expanded further from 12.3% in the previous quarter, demonstrating tangible progress in the global business. - FY2019-Q1AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 3.5 percentage points year on year to 12.3%.」
The overseas sales ratio rose by 3.5 percentage points year on year to 12.3%, recovering from the decline in the previous fiscal year. This is a measurable improvement indicating progress in the global business. - FY2018WorsenedAnnual report
「In overseas markets, we will focus on niche markets and seek to expand sales of products that capitalize on our technological capabilities. The ratio of overseas sales to total sales decreased by 0.8 percentage points from the previous fiscal year to 9.8%.」
The policy of expanding sales in overseas niche markets continues, but the overseas sales ratio fell from 10.6% in the previous fiscal year to 9.8%, and overseas sales decreased by 5.2% from the previous fiscal year. - FY2018-Q3WorsenedAnnual report
「The ratio of overseas sales to total sales decreased by 0.8 percentage points year on year to 10.1%.」
The overseas sales ratio fell by 0.8 percentage points year on year to 10.1%, indicating deterioration in the latest progress of the global business. - FY2018-Q2WorsenedAnnual report
「However, as sales opportunities for the systems themselves declined in both domestic and overseas markets, sales for the cumulative second quarter amounted to ¥3,414.155 million, down 9.3% year on year. The ratio of overseas sales to total sales was 9.4%.」
The overseas sales ratio was 9.4%, down from 9.7% in the same period of the previous year. Against the backdrop of fewer overseas sales opportunities for the systems themselves, progress in the global business has deteriorated. - FY2018-Q1WorsenedAnnual report
「As sales opportunities for the systems themselves declined in both domestic and overseas markets, particularly overseas, the ratio of overseas sales to total sales decreased by 1.4 percentage points year on year to 8.8%.」
Sales opportunities for the systems themselves declined in overseas markets, and the overseas sales ratio fell by 1.4 percentage points year on year to 8.8%. Progress in the global business has deteriorated in the latest quarter. - FY2017AdvancedAnnual report
「Overseas sales amounted to ¥892.531 million, up 11.7% from the previous fiscal year, as sales of both blood collection tube preparation systems and specimen testing systems grew in the Asian market. The ratio of overseas sales to total sales increased by 1.8 percentage points from the previous fiscal year to 10.6%.」
Overseas sales increased by 11.7% from the previous fiscal year as sales in the Asian market grew, while the overseas sales ratio rose to 10.6%. - FY2017-Q3AdvancedAnnual report
「As a result of active sales efforts for blood gas and electrolyte analyzers in both domestic and overseas markets, domestic sales amounted to ¥272.699 million, up 3.2% year on year, while overseas sales amounted to ¥92.289 million, up 84.2%. The ratio of overseas sales to total sales increased by 1.7 percentage points year on year to 10.9%.」
Overseas sales of blood gas and electrolyte analyzers increased by 84.2% year on year, while the overseas sales ratio rose by 1.7 percentage points year on year to 10.9%. - FY2017-Q2AdvancedAnnual report
「We will focus on stimulating replacement demand in the domestic market and developing markets overseas, centered on new models of blood collection tube preparation systems and specimen testing systems, with the aim of increasing cumulative unit sales and steadily expanding sales of consumables and other products associated with these systems. The ratio of overseas sales to total sales increased by 0.5 percentage points year on year to 9.7%.」
While continuing to develop overseas markets, the overseas sales ratio rose by 0.5 percentage points year on year to 9.7%. - FY2017-Q1AdvancedAnnual report
「The ratio of overseas sales to total sales increased by 2.3 percentage points year on year to 10.2%.」
The overseas sales ratio rose by 2.3 percentage points year on year to 10.2%. This represents measurable progress in the expansion of the overseas business, although no specific expansion initiatives are described here. - FY2016First statedAnnual report
「With respect to retained earnings, we intend to make effective investments in continuous technological innovation to respond swiftly to dramatic changes in society and healthcare, actively conduct research and development of innovative products that meet market needs, and develop global business strategies, thereby improving earnings and returning profits to shareholders.」
New product research and development and global business strategies are identified as effective investment areas for retained earnings.